Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Gilead Sciences (NASDAQ:GILD) announced its earnings results on Thursday. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36, FiscalAI reports. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the business posted $2.47 earnings per share. Gilead Sciences’s quarterly revenue was up 6.8% on a year-over-year basis.

Here are the key takeaways from Gilead Sciences’ conference call:

• Strong third-quarter execution: Base business sales rose 16% year over year to $8.2 billion, led by HIV products, TRODELVY, and Livdelzi. Gilead raised its 2026 base-business revenue guidance by $900 million at the midpoint.
• HIV momentum remained robust, with sales up 18% and BIKTARVY reaching a record 53% U.S. treatment share. Yeztugo sales reached $305 million for the quarter and are tracking toward approximately $1 billion for the full year, while the Bixlenvo launch is reportedly progressing ahead of comparable launches.
• The company highlighted a broadening growth pipeline, including a potential 2027 filing for once-weekly oral HIV treatment, additional long-acting HIV options, seven clinical-stage oncology ADC programs, and 13 inflammation programs. Management also expects a potential anito-cel approval in December for relapsed or refractory multiple myeloma.
• CMS set BIKTARVY’s Medicare price at $2,600 per 30-day supply, approximately 38% below list price. Gilead preliminarily estimates a roughly $1.5 billion net revenue impact in 2028, including spillover effects across Medicaid, 340B, and other U.S. channels.
• Cell therapy sales declined 18% year over year because of competitive pressure, and the PALISADES-1 and -2 studies of KITE-753 are on partial clinical hold while the company investigates higher-grade ICANS differences between trial phases. Gilead said there were no patient deaths but paused the studies pending further review.

Gilead Sciences Trading Up 3.1%

Shares of Gilead Sciences stock traded up $5.07 on Friday, hitting $170.68. The stock had a trading volume of 11,425,175 shares, compared to its average volume of 5,950,684. The stock has a 50 day moving average of $150.87 and a 200 day moving average of $139.79. The firm has a market capitalization of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.31. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $175.65. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wells Fargo & Company boosted their price target on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday. Needham & Company LLC set a $175.00 target price on shares of Gilead Sciences in a report on Friday. Bank of America boosted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday. Finally, Barclays cut their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the transaction, the chief executive officer directly owned 566,683 shares of the company’s stock, valued at $83,812,415.70. The trade was a 2.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock worth $15,877,860 over the last quarter. Insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.